Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KIT(AY502-3ins) mutation: an in vitro mutagenesis screen for drug-resistance

PURPOSE: While tyrosine kinase inhibitors (TKI) have improved survival in advanced GIST, complete response is rare and most patients eventually fail the first line treatment with imatinib. Sunitinib malate is the only approved 2(nd) line therapy for patients with imatinib-resistant or -intolerant GI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Guo, Tianhua, Hajdu, Mihai, Agaram, Narasimhan P, Shinoda, Hiroko, Veach, Darren, Clarkson, Bayard D., Maki, Robert G, Singer, Samuel, DeMatteo, Ronald P, Besmer, Peter, Antonescu, Cristina R
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2783687/
https://ncbi.nlm.nih.gov/pubmed/19861442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1315
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados